Reneo Pharmaceuticals
IPO
- Headquarters
- San Diego, California
- Employees
- 11–50
- Founded
- 2014
- Business Model
- B2B
- Website
- reneopharma.com
- Total Funding
- $145.0M
- Last Round
- $95.0M Series BDec 2020
About
Reneo Pharmaceuticals was a clinical-stage biopharmaceutical company founded in 2014 in San Diego, California, focused on the development of therapies for patients with rare genetic mitochondrial diseases. Reneo's lead program, REN001 (a PPARdelta agonist), targeted primary mitochondrial myopathy. The company went public on Nasdaq in April 2021 under the symbol RPHM. Following a Phase 2b clinical trial failure in May 2024, Reneo merged with OnKure Therapeutics, closing the merger in October 2024.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account